| abstract |
The present invention relates to a method for predicting patient responsiveness to treatment with a TNF-α blocker comprising the guanine at position 238, the guanine at position 308, and the position 857 of the patient's TNF-α gene. A method comprising determining the presence or absence of cytosine, wherein the guanine at position 238, the guanine at position 308, and the position 857 of the TNF-α gene in both copies of the TNF-α gene of the patient. Relates to a method wherein the simultaneous presence of cytosine indicates a reduced likelihood of the patient's responsiveness to treatment with a TNF-α blocker compared to standard responsiveness. |